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Kocsis GF, Sárközy M, Bencsik P, Pipicz M, Varga ZV, Pálóczi
J, Csonka C, Ferdinandy P, Csont T. Preconditioning protects the
heart in a prolonged uremic condition. Am J Physiol Heart Circ
Physiol 303: H1229–H1236, 2012. First published September 14,
2012; doi:10.1152/ajpheart.00379.2012.— Metabolic diseases such as
hyperlipidemia and diabetes attenuate the cardioprotective effect of
ischemic preconditioning. In the present study, we examined whether
another metabolic disease, prolonged uremia, affects ischemia/reper-
fusion injury and cardioprotection by ischemic preconditioning. Ure-
mia was induced by partial nephrectomy in male Wistar rats. The
development of uremia was verified 29 wk after surgery. Transtho-
racic echocardiography was performed to monitor cardiac function. At
week 30, hearts of nephrectomized and sham-operated rats were
isolated and subjected to a 30-min coronary occlusion followed by
120 min reperfusion with or without preceding preconditioning in-
duced by three intermittent cycles of brief ischemia and reperfusion.
In nephrectomized rats, plasma uric acid, carbamide, and creatinine as
well as urine protein levels were increased as compared with sham-
operated controls. Systolic anterior and septal wall thicknesses were
increased in nephrectomized rats, suggesting the development of a
minimal cardiac hypertrophy. Ejection fraction was decreased and
isovolumic relaxation time was shortened in nephrectomized rats
demonstrating a mild systolic and diastolic dysfunction. Infarct size
was not affected significantly by nephrectomy itself. Ischemic pre-
conditioning significantly decreased infarct size from 24.8  5.2% to
6.6  1.3% in the sham-operated group and also in the uremic group
from 35.4  9.5% to 11.9  3.1% of the area at risk. Plasma ANG II
and nitrotyrosine were significantly increased in the uremic rats. We
conclude that although prolonged experimental uremia leads to severe
metabolic changes and the development of a mild myocardial dys-
function, the cardioprotective effect of ischemic preconditioning is
still preserved.
chronic renal failure; myocardium; ischemic preconditioning; infarct
size; myocardial function
ISCHEMIC PRECONDITIONING IS a well-characterized endogenous
adaptive response of the myocardium in which brief cycles of
ischemia markedly enhance the ability of the heart to withstand
a subsequent ischemic injury (15). Although preconditioning
confers remarkable cardioprotection in a variety of species (15,
44), including humans (21, 49, 55), we and others have shown
that its effectiveness is attenuated by some risk factors and
comorbidities such as metabolic diseases including hyperlip-
idemia (14–16) and diabetes (35, 54) both in animal models
and humans (15).
Increasing prevalence of hyperlipidemia and diabetes in the
aging population results in a dramatic rise in the prevalence of
chronic kidney disease characterized by severe metabolic
changes generally termed as uremia. The majority of patients
suffering from uremia remain unaware of their condition for
several years until reaching late stages of chronic kidney
disease (5, 37). Uremia and especially end-stage renal failure
have been shown to increase the risk of cardiovascular mor-
bidity and mortality (18, 24). The prevalence of coronary artery
disease at the start of dialysis is 40% (53). In fact, cardio-
vascular disease is the main cause of death in patients with
chronic renal failure (18, 50). The incidence of myocardial
infarction is high in dialysis patients, and the outcome after
myocardial infarction is poor (2). Left ventricular dysfunction
is notable in a significant number of patients on chronic
dialysis, especially after acute myocardial infarction (2, 19,
26). One may speculate that the metabolic changes seen in
uremia may interfere with endogenous cardioprotective mech-
anisms as seen with other metabolic diseases. However, there
are limited data on the possible interaction of uremia with
endogenous adaptive cardioprotective mechanisms including
pre- and postconditioning.
A preliminary study from our research group has previously
demonstrated for the first time in the literature that the infarct
size limiting effect of ischemic postconditioning is still pre-
served in experimental chronic renal failure 10 wk after sub-
total nephrectomy (32). Byrne et al. (4) has recently reported
that ischemic preconditioning, remote ischemic conditioning,
and ischemic postconditioning are still cardioprotective after
4 wk of subtotal nephrectomy. These studies may suggest that
the uremic heart can still be protected by conditioning tech-
niques. However, an experimental model of 4 wk of uremia
may not properly reflect the clinical situation, since uremia
remains unexplored until late stages of kidney disease in a
significant number of patients (8). Thus the effect of prolonged
experimental uremia on the cardioprotective effect elicited by
endogenous cardioprotective mechanisms is still not known
(8); however, the duration of the uremic condition may be an
important determinant of the efficacy of ischemic pre- and
postconditioning (8). Indeed, it has been shown earlier that
2 wk (54) of experimental diabetes protected the myocardium
against ischemia/reperfusion injury; however, 4 or 8 wk of
experimental diabetes abolished the protection by ischemic
preconditioning (15, 54).
Therefore, in the present study we examined the influence of
prolonged uremia (30 wk) on the severity of ischemia/reper-
fusion injury and the infarct size limiting effect of ischemic
preconditioning.
MATERIALS AND METHODS
This investigation conforms to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH Publication
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No. 85-23, Revised 1996) and was approved by the Animal Research
Ethics Committee of the University of Szeged.
Adult male Wistar rats were used in the study. Animals were
housed in pairs in individually ventilated cages (Sealsafe IVC system,
Italy) and were maintained in a temperature-controlled room with a
12-h:12-h light/dark cycles throughout the study. Standard rat chow
and tap water were supplied ad libitum. Drinking water contained 1
mg/100 g body wt iron (II) sulfate to attenuate the development of
severe anemia.
Experimental setup. Experimental prolonged uremia was induced
by partial (5/6) nephrectomy. Animals underwent sham operation or
partial nephrectomy in two phases (Fig. 1) (42). There was no
difference in mortality between sham-operated and partially nephrec-
tomized groups. At week 29, cardiac function was assessed by trans-
thoracic echocardiographic examination. At week 29, a group of
animals were placed for 24 h in metabolic cages to estimate creatinine
clearance and to measure urine creatinine and protein levels. At week
30, rats were anesthetized, and hearts were isolated and perfused
ex vivo by oxygenated Krebs-Henseleit solution according to Lan-
gendorff as described previously (31). Immediately after excision of
the heart, blood was collected from the thoracic cavity to measure
plasma uric acid, carbamide, and creatinine levels to verify the
development of uremia. Some plasma was used for the determination
of ANG II as an indirect marker of hypertension and hypertrophy (20,
27, 28, 43, 58) and nitrotyrosine as a marker of systemic nitrosative
stress (7). To assess the cardioprotective effect of ischemic precon-
ditioning in the hearts of uremic and sham-operated animals, the
perfused hearts were subjected to ischemia/reperfusion with or with-
out preconditioning protocol. At the end of the appropriate perfusion
protocol, the coronary artery was reoccluded and the area at risk and
the infarcted area were delineated using an Evans blue/triphenyltet-
razolium chloride double staining method (6).
Partial nephrectomy. Anesthesia was induced by intraperitoneal
injection of pentobarbital sodium (Euthasol; 50 mg/kg; Produlab
Pharma b.v., Raamsdonksveer, The Netherlands). After depilation and
a ventral midline incision in the abdominal wall, the intestines were
retracted laterally to expose the animal’s left kidney. The kidney was
freed from the perirenal adipose tissue and renal capsule. Two pieces
of sutures (5-0 Mersilk; Ethicon, Sommerville, NJ) were placed
around both poles of the kidney approximately at their 1/3 position.
The sutures were gently ligated around the kidney. The 1/3 kidney on
both ends was excised right beyond the ligatures. The abdominal
incision was closed with running sutures. One week after the first
operation, animals were anesthetized and prepared as described above
(42). The right kidney was freed from the surrounding adipose tissue
and renal capsule, and then it was pulled out of the incision gently.
The adrenal gland, which is attached loosely to the anterior pole of the
kidney, was gently freed and was placed back into the abdominal
cavity. The renal blood vessels and the ureter were ligated, and the
right kidney was removed (29). The incision was then closed with
running sutures, and povidone iodide was applied on the surface of the
skin. After operation, animals were placed on a warm heating pad
until they become conscious again. As a post-operative medication,
0.3 mg/kg nalbuphine hydrochloride (Nalbuphine 10 mg/ml; TEVA,
Debrecen, Hungary) was administered subcutaneously. Antibiotics
(Enroxil, 75 mg; Krka, Slovenia) and analgesics (10 mg/l of nalbu-
phine hydrochloride, Nalbuphine; TEVA) were administered in tap
water for 2 days after both surgeries.
Transthoracic echocardiography. Cardiac function was assessed
by transthoracic echocardiographic examination 29 wk after the sec-
ond surgery. Echocardiography was performed as described previ-
ously (39). The rats were anesthetized with pentobarbital sodium
(Euthasol, 40 mg/kg body wt ip), the chest was shaved, and the animal
was placed in supine position onto a heating pad. Two-dimensional,
M-mode and Doppler echocardiographic examinations were per-
formed in accordance with the criteria of the American Society of
Echocardiography with a Vivid 7 Dimension ultrasound system (Gen-
eral Electric Medical Systems) using a phased array 5.5–12 MHz
transducer (10S probe). Data of three consecutive heart cycles were
analyzed (EchoPac Dimension software; General Electric Medical
Systems) by an experienced investigator in a blinded manner. The
mean values of three measurements were calculated and used for
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Fig. 1. Wistar rats underwent sham operation or partial nephrectomy in 2 phases. First, 2/3 of the left kidney was ligated and excised (Op1). One week later,
the right kidney was removed (Op2). Corresponding time-matched sham operations were performed in the sham group. At week 29, cardiac function was assessed
by transthoracic echocardiographic examination (Echo). In this week the animals (12–12 in uremia and sham groups) were placed for 24 h in a metabolic cage
(Metabolism) to determine urine creatinine and protein levels. At week 30, rats were anesthetized and blood was collected from thoracic cavity to measure plasma
carbamide and creatinine levels (Plasma). Hearts were then isolated and perfused according to Langendorff. After 15 min of aerobic perfusion, hearts were
subjected to either preconditioning induced by 3 intermittent periods of 5-min ischemia/reperfusion (I/R) cycles or a time-matched (30 min) aerobic perfusion,
both followed by a 30-min coronary occlusion and 2-h reperfusion (n 6–9 in each group). Coronary flow (CF) was measured 10 min after the start of perfusion,
in the 15th min of ischemia, in the first 5 min of reperfusion and at the end of the reperfusion. IPre, ischemic preconditioning (IPre).
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statistical evaluation. Systolic and diastolic wall thickness parameters
were obtained from parasternal short-axis view at the level of the
papillary muscles and long-axis view at the level of the mitral valve.
The left ventricle diameters were measured by means of M-mode
echocardiography from long-axis and short-axis views between the
endocardial borders. Functional parameters including left ventricular
end-diastolic volume, left ventricular end-systolic volume, and ejec-
tion fraction were calculated on four-chamber view images. Diastolic
function was assessed using pulse-wave Doppler across the mitral
valve from the apical four-chamber view. Early (E) and atrial (A) flow
velocity as well as mitral valve deceleration time and isovolumic
relaxation time provide an indication of diastolic function.
Urine creatinine and total protein levels. At week 29, the animals
were placed in a metabolic cage (Techniplast, Italy) for 24 h to collect
urine for the measurement of urine creatinine and protein levels to
verify the development of advanced uremia.
Urine creatinine and urine protein levels were measured by stan-
dard laboratory methods as described previously by others (11, 40).
Plasma carbamide and creatinine levels. Blood was collected from
the thoracic cavity after isolation of the heart to measure plasma
carbamide and creatinine levels to verify the development of chronic
uremia at week 30. Plasma carbamide and creatinine levels were
measured in triplicate, using commercially available colorimetric
assay kits (Diagnosticum, Budapest, Hungary) applying enzymatic
determinations adapted to 96-well plates.
Creatinine clearance. Creatinine clearance, an indicator of renal
function, was calculated according to the standard formula (urine
creatinine concentration [M]  urine volume for 24 h [ml])/(plasma
creatinine concentration [M]  24  60 min).
Hematocrit and hemoglobin level. Hematocrit and hemoglobin
were measured from whole blood by means of a blood gas analyzer
(Radiometer ABL 77; Radiometer Medical, Bronshoj, Denmark) at
week 30 to verify the development of renal anemia.
Ex vivo cardiac perfusions and infarct size determination. At week
30, rats were anesthetized and hearts were isolated and perfused at
37°C according to Langendorff with oxygenated Krebs-Henseleit
buffer as previously described (14, 31). Hearts from the sham-
operated and the uremic groups were further subdivided into two
subgroups (n  6–9) and subjected to either a nonconditioning or a
preconditioning perfusion protocol, respectively (Fig. 1). Noncondi-
tioned hearts were subjected to time-matched aerobic perfusion fol-
lowed by test ischemia-reperfusion induced by a 30-min occlusion of
the left descending coronary artery. Preconditioned hearts were sub-
jected to three intermittent periods of 5-min ischemia/reperfusion
followed by test ischemia/reperfusion. A 3-0 silk suture was placed
around the origin of the left descending coronary artery and passed
through a plastic tube to form a snare. After stabilization of the heart,
coronary occlusion was induced by pulling the ends of the suture taut
and clamping the snare onto the epicardial surface. Reperfusion was
achieved by releasing the snare as previously described (9, 31). Heart
rate and coronary flow were monitored throughout the perfusion
protocol (Fig. 1). At the end of the 2-h reperfusion protocol, the
coronary artery was reoccluded and 5 ml of 0.1% Evans blue dye
(Merk, Germany) was injected into the aorta to delineate the area-at-
risk zone. Stained hearts were weighed, frozen, sliced, and incubated
at 37°C in 1% triphenyl-tetrazolium chloride (Sigma Aldrich, Ger-
many) to delineate infarcted tissue. Slices were then fixed and quan-
tified by planimetry using Infarctsize 2.5 software (Pharmahungary,
Szeged, Hungary) (31). Infarct size was expressed as a percentage of
the area-at-risk zone (6). The area at risk was calculated as a percent-
age of total ventricular area (6).
Plasma ANG II level. Plasma ANG II level was determined as a
marker of hypertension and left ventricular hypertrophy. The level of
ANG II in blood plasma of uremic and sham-operated rats was
determined with enzyme linked immunosorbent assay (ELISA) kits
recognizing rat peptides (Phoenix Pharmaceuticals) in accordance
with the manufacturer’s instructions.
Plasma 3-nitrotyrosine level. Plasma 3-nitrotyrosine level was
determined as a marker of systemic nitrosative stress. Free 3-nitroty-
rosine level was measured by ELISA (Cayman Chemical) as de-
scribed earlier (7) from sham and uremic plasma samples taken at
week 30. Briefly, supernatants of deproteinized plasma samples were
concentrated and then incubated overnight with anti-nitrotyrosine
rabbit IgG specific to free 3-nitrotyrosine and nitrotyrosine acetylcho-
linesterase tracer in precoated (mouse anti-rabbit IgG) microplates
followed by development with Ellman’s reagent. Free nitrotyrosine
content was expressed as nanograms per milliliter plasma.
0
4
8
12
Sham Uremia
* 
P
la
sm
a 
ca
rb
am
id
e 
(m
m
ol
/l)
 
0
100
200
300
Sham Uremia
* 
P
la
sm
a 
cr
ea
tin
in
e 
(µ
m
ol
/l)
 
0
4
8
12
Sham Uremia
U
rin
e 
cr
ea
tin
in
e 
(m
m
ol
/l)
 
 C B
 F E D
A 
p=0.0500 
0
4
8
12
Sham Uremia
C
re
at
in
in
e 
cl
ea
ra
nc
e 
 
(m
l/m
in
) 
p=0.1098 
* * 
* * 
0
1
2
3
Sham Uremia
* 
U
rin
e 
pr
ot
ei
n 
(g
/d
l) 
0
200
400
600
800
-1 11 23 35
A
ni
m
al
 w
ei
gh
t (
g)
 
 weeks 
Fig. 2. Animal weight (A) shown in every 6 wk.
Solid line, Sham; dashed line, uremia. Plasma
carbamide (B; n  14 in both groups) and
creatinine (C, n  12–15), urine creatinine (D;
n  12 in each groups) and protein concentra-
tions (E; n  10–12) and creatinine clearance
(F; n  9 to 10) in both sham-operated and
uremic rats are shown. Values are means SE.
*P  0.05.
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Plasma uric acid level. Plasma uric acid level was measured to
further characterize our uremic model. Plasma uric acid level was
measured in duplicate, using a commercially available colorimetric
assay kit (Diagnosticum, Budapest, Hungary) according to the man-
ufacturer’s instructions.
Statistical analysis. All values are presented as means  SE.
Two-way ANOVA was used to determine the effect of uremia or
preconditioning on infarct size, area at risk, and coronary flow. To
analyze the effect of preconditioning on infarct size within sham-
operated as well as uremic groups, an unpaired t-test was then applied.
All other parameters were analyzed by unpaired t-tests comparing
data in the uremic groups with sham-operated controls. P  0.05 was
accepted as a statistically significant difference.
RESULTS
Characterization of prolonged uremia. To verify the devel-
opment of long-term uremia induced by partial nephrectomy,
body weight was monitored during the experiment and con-
centrations of several plasma and urine metabolites were mea-
sured at week 29. Partially nephrectomized rats showed signif-
icantly lower body weights starting from week 7 showing
uremic cachexia (Fig. 2A). Plasma carbamide and creatinine
levels were markedly increased in partially nephrectomized
rats representing the uremic state of these animals (Fig. 2, B
and C). Plasma glucose levels were similar in both the sham-
operated and the partially nephrectomized groups (5.7  0.1
vs. 5.0  0.2; n  13–16; not significant). Urine protein
concentration was significantly increased in the partially ne-
phrectomized rats as compared with sham-operated controls
(Fig. 2E) showing an impaired renal function. Moreover, urine
creatinine level and creatinine clearance showed a marked but
statistically not significant decrease at the level of P  0.05 in
partially nephrectomized rats (Fig. 2, D and F). Hematocrit and
hemoglobin levels were significantly decreased in uremic an-
imals (44.7  2.2% and 15.0  0.7 g/dL, respectively; n  6)
when compared with sham-operated rats (54.2  1.0% vs. and
17.7  0.3 g/dL respectively; n  10) showing renal anemia.
Effect of prolonged uremia on myocardial morphology and
function. Transthoracic echocardiography was performed at week
29 to investigate whether the development of prolonged uremia
leads to alteration of myocardial morphology and function. Left
Table 1. Effects of uremia on various in vivo left ventricular morphological and functional parameters measured
by transthoracic echocardiography
Echocardiography
View/Mode Sham Uremia P Value
Morphology
n 14 16
Wall thickness, mm
Anterior
Systolic short axis/MM 3.31 0.05 3.59  0.11* 0.032
Diastolic short axis/MM 1.87 0.07 1.97  0.09 0.371
Lateral
Systolic short axis/MM 3.47 0.11 3.38  0.18 0.796
Diastolic short axis/MM 2.14 0.40 1.98  0.08 0.270
Posterior
Systolic long axis/MM 3.77 0.11 3.81  0.11 0.781
Diastolic long axis/MM 2.18 0.07 2.30  0.08 0.287
Septal
Systolic long axis/MM 2.70 0.12 3.04  0.13* 0.046
Diastolic long axis/MM 2.25 0.10 2.26  0.08 0.961
Left ventricular end-diastolic diameter, mm long axis/MM 7.25 0.17 6.95  0.14 0.176
Left ventricular end-diastolic diameter, mm short axis/MM 7.23 0.18 7.23  0.19 0.967
Left ventricular end-systolic diameter, mm long axis/MM 3.82 0.16 3.55  0.15 0.237
Left ventricular end-systolic diameter, mm short axis/MM 3.77 0.20 3.53  0.19 0.400
Systolic function
n 14 16
Ejection fraction, % four chamber/2D 54.9 1.7 48.9  1.4* 0.012
Stroke volume, l four chamber/2D 252.2  13.8 222.9  10.1 0.093
Left ventricular volume, l
End systolic four chamber/2D 219.3 23.1 240.0  18.7 0.487
End diastolic four chamber/2D 477.0 36.1 461.7  27.3 0.736
Heart rate, beats/min four chamber/2D 391.1 6.9 396.1  4.9 0.565
Diastolic function - Doppler imaging
n 13 14
E-wave, m/s four chamber/PW 0.82 0.03 0.85  0.03 0.664
A-wave, m/s four chamber/PW 0.50 0.03 0.51  0.02 0.889
E-to-A ratio four chamber/PW 1.69 0.07 1.72  0.09 0.830
Deceleration time, ms four chamber/PW 33.98 1.95 34.39  1.75 0.885
Isovolumic relaxation time, ms four chamber/PW 25.05 0.89 21.69  0.9* 0.025
Left ventricular gradient, mmHg
Maximal four chamber/PW 2.89 0.25 3.09  0.24 0.598
Mean four chamber/PW 1.31 0.10 1.47  0.12 0.351
Values are means SE; n 13–16. Transthoracic echocardiographic measurements were performed 29 wk after sham operation or partial nephrectomy. *P  0.05
vs. sham, unpaired t-test. MM, M (motion) mode; 2D, 2-dimensional; PW, pulse wave; E-wave, early ventricular filling velocity; A-wave, late or atrial ventricular
filling velocity.
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ventricular systolic anterior and septal wall thicknesses were
increased in uremic rats as compared with sham-operated controls
(Table 1). However, there was no difference in diastolic ante-
rior and septal wall thickness between the uremic and sham-
operated group. In addition, left ventricular lateral and poste-
rior wall thickness both in systole and diastole were similar in
the uremic and the sham-operated groups (Table 1). Uremic
animals demonstrated a mild reduction both in left ventricular
systolic and diastolic function at week 29. Ejection fraction was
significantly reduced in the uremic group as compared with the
sham-operated control group (Table 1). Stroke volume showed
a tendency of decrease in uremic animals as compared with
sham-operated controls (Table 1). Heart rate and left ventric-
ular end-systolic and end-diastolic volumes were similar in
both uremic and sham-operated groups (Table 1). Isovolumic
relaxation time was decreased in uremic rats as compared with
sham-operated controls (Table 1). Other diastolic functional
parameters including early and late ventricular filling velocity,
E/A ratio, deceleration time, and maximal and mean left
ventricular gradient were not changed in the uremic group as
compared with sham-operated controls (Table 1).
Effect of prolonged uremia on ex vivo morphological and
functional parameters. Coronary flow and morphological pa-
rameters including heart weight, left kidney weight, and tibia
length were measured at week 30 to investigate whether ad-
vanced uremia influences ex vivo functional and morphologi-
cal parameters of the heart. Coronary flow was significantly
reduced in uremic groups when compared with corresponding
sham-operated control groups as assessed by two-way
ANOVA (Table 2). The ratio of heart weight to body weight
showed a tendency of increase in uremic animals (Table 3), as
a result of a significantly lower body weight in the uremic
group (Fig. 2A). However, there was no difference in heart
weight and heart weight-to-tibia length ratio between the ure-
mic and the sham-operated control group (Table 3). In addi-
tion, the weight of the whole left kidney in the sham-operated
group and the remaining one-third of the left kidney in the
uremic group were similar, suggesting a marked renal hyper-
trophy in the uremic animals (Table 3).
Effect of ischemic preconditioning on infarct size. Infarct
size was measured at week 30 to investigate the severity of
ischemia/reperfusion injury and the cardioprotective effect of
ischemic preconditioning in prolonged uremia (Fig. 3A). Pre-
conditioning significantly decreased infarct size; however, the
presence of prolonged uremia did not significantly influence
the size of infarction as assessed by two-way ANOVA. Addi-
tional analysis with unpaired t-tests showed a significant infarct
size limiting effect of preconditioning in hearts of both uremic
and sham-operated rats (Fig. 4B). The area-at-risk zone was not
affected significantly in any of the groups (Fig. 4A).
Effect of prolonged uremia on plasma ANG II, 3-nitroty-
rosine, and uric acid levels. Partially nephrectomized rats
showed significantly higher plasma ANG II level (Fig. 4A),
which is a well-known marker of hypertension and left ven-
tricular hypertrophy.
Plasma 3-nitrotyrosine level was determined as a marker of
peroxynitrite and systemic nitrosative stress. Plasma 3-nitroty-
rosine level was markedly increased in uremic rats as com-
pared with sham-operated controls, representing increased sys-
temic nitrosative stress in uremic animals (Fig. 4B).
Plasma level of uric acid, a well-known antioxidant, was
significantly increased in the partially nephrectomized rats as
compared with sham-operated controls (Fig. 4C) showing
increased antioxidant capacity in uremic rats.
DISCUSSION
We have found here that although 30 wk of experimental
renal failure leads to severe metabolic changes and the devel-
opment of myocardial dysfunction, the cardioprotective effect
of ischemic preconditioning is still observed. This is the first
demonstration that prolonged uremia does not interfere with
the cardioprotective effect of ischemic preconditioning.
The cardioprotective effect of ischemic pre- and postcondi-
tioning is inhibited by several comorbid conditions and risk
factors such as aging (3, 47, 59), hyperlipidemia (14–17, 23,
36, 55), and diabetes (35, 48, 54). However, recent evidence
suggests that the cardioprotective effect of pre- and postcon-
ditioning is maintained in subacute renal failure (4 wk) (4) and
short-term (10 wk) (32) model of uremia. In a preliminary
study, we have demonstrated for the first time in the literature
that the infarct size limiting effect of postconditioning was still
present 10 wk after subtotal nephrectomy, resulting in uremia
in rats (32). Moreover, an extensive study recently published
by Byrne et al. (4) has reported that ischemic preconditioning,
remote ischemic conditioning, and ischemic postconditioning
are still cardioprotective after 4 wk of subtotal nephrectomy. In
addition, in the same study ischemic preconditioning was
Table 3. Effect of uremia on various ex vivo morphological
parameters
Measurement Sham Uremia P Value
n 14 12
Heart weight, g 2.10 0.09 2.10  0.10 0.980
Heart weight/body
weight  103 3.40  0.17 3.77  0.15 0.126
Heart weight/tibia
length  102 4.00  0.20 4.20  0.20 0.483
Left kidney weight, g Full kidney weight 1/3 kidney weight —
1.90  0.11 2.04  0.09
Values are means  SE; n  12–14, unpaired t-test. Measurements were
performed 30 wk after sham operation or partial nephrectomy.
Table 2. Effects of uremia on ex vivo coronary flow data
Coronary flow
Time points of the measurements Sham Uremia P Value
During nonconditioning perfusion protocol
n 8 9
Baseline, ml/min 16.9 1.3 13.1  1.1* 0.044
15th min of ischemia, ml/min 8.6  0.9 7.4  0.5 0.260
First 5 min of reperfusion, ml/min 19.0  1.3 16.9  1.6 0.367
End of reperfusion, ml/min 13.0 0.7 9.4  1.1* 0.023
During preconditioning perfusion protocol
n 6 7
Baseline, ml/min 17.5 1.1 13.0  0.6* 0.007
15th min of ischemia, ml/min 8.6  0.7 6.4  0.7 0.071
First 5 min of reperfusion, ml/min 22.2  1.1 15.5  1.7* 0.016
End of reperfusion, ml/min 14.1 0.9 8.4  0.8* 0.003
Values are means  SE; n  6–9. Studies were performed on ex vivo
Langendorff heart perfusion system 30 wk after sham operation or partial
nephrectomy, *P  0.05 vs. sham, unpaired t-test.
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shown to limit infarct size in an adenine-enriched diet-induced
model of uremia in rats (4). Although the uremic state seems to
be too short and was not characterized thoroughly in Byrne’s
aforementioned studies (4, 8), they may suggest that the uremic
heart can be still protected by conditioning techniques. Indeed,
an experimental model of 4 wk of uremia probably may not
properly reflect the clinical situation, since uremia may remain
unexplored for a long time in patients (8, 37). Additionally, it
has been shown that 5/6 partial nephrectomy followed by a
postoperative duration of 3 wk does not lead to advanced
uremia in rats (10).
Therefore, in the present study we used a prolonged (30 wk)
postoperative duration following partial nephrectomy to induce
a more severe long-term uremic condition for investigating the
cardioprotective effect of preconditioning. In this model, here
we have found characteristic biochemical and pathophysiolog-
ical signs of prolonged uremia, including cachexia, increased
plasma uric acid, carbamide and creatinine levels, decreased
hematocrit and hemoglobin, increased urine protein, and de-
creased creatinine concentration, as well as diminished creat-
inine clearance. In patients with end-stage renal failure, uremic
cardiomyopathy is a common complication and reported to be
a prognostic factor of cardiovascular mortality (24, 50, 53). In
the present study, we have found increased septal and anterior
wall thickness in uremic animals. Additionally, plasma ANG II
level, which is an indirect marker of hypertension and left
ventricular hypertrophy (20, 27, 28, 43, 58), was also higher in
uremic rats. These results together with literature data (1, 33,
38, 41) suggest the development of a minimal left ventricular
hypertrophy in uremic animals at week 30 in our present study.
In this model, we have found here that ischemic precondition-
ing is still effective in prolonged uremic condition. This is a
refreshingly interesting result in the light of the fact that several
metabolic diseases including diabetes and hyperlipidemia in-
hibit the endogenous cardioprotective mechanisms of ischemic
conditioning.
The reason why the complex metabolic changes of uremia,
which significantly affect several intracellular signaling path-
ways in the heart and lead to myocardial dysfunction, do not
affect the overall efficacy of cardioprotection by ischemic
preconditioning is unknown. It has been previously shown that
6- to 8-wk-long chronic renal failure leads to increased oxida-
tive and nitrosative stress in the rat heart (1, 51, 56, 57). Here
we have also shown increased nitrosative stress in a 30-wk
model of prolonged uremia. It is well known that the cardio-
protective effect of ischemic preconditioning is lost in meta-
bolic diseases associated with increased myocardial oxidative
and nitrosative stress (15). Therefore, our present findings
showing that the cardioprotective effect of ischemic precondi-
tioning is surprisingly still preserved in uremic animals despite
the increased systemic nitrosative stress are particularly excit-
ing. These results suggest that even though prolonged uremia
leads to some deleterious effects (e.g., mild cardiac dysfunc-
tion, tendency of increased infarct size), it likely induces some
complex compensatory alterations supporting maintained car-
dioprotection by ischemic preconditioning. This hypothesis is
further supported by our present finding showing elevated
plasma levels of uric acid, a known antioxidant, in prolonged
uremia. However, further studies should be carried out to
determine the precise role of oxidative/nitrosative stress in the
mechanism of preconditioning in uremia.
Upregulation of renal renin-angiotensin-aldosterone system
was also shown in rats with partial nephrectomy in our present
study similarly to findings of other research groups (25, 33,
41). In our present study, increased plasma ANG II levels
together with echocardiographic data suggest the development
of a minimal left ventricular hypertrophy at week 30 in uremic
animals. In this aspect our study is in line with other studies
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showing that ischemic preconditioning is still cardioprotective
in case of left ventricular hypertrophy (45, 52) and hyperten-
sion (12, 13, 52) associated with increased plasma ANG II
level (15). Therefore, we believe that the presence of a minimal
cardiac hypertrophy and mild left ventricular dysfunction in
uremic animals might not interfere with the cardioprotective
mechanism of ischemic preconditioning. However, it cannot be
excluded that the cardioprotection by preconditioning may be
lost with the progression of the disease and development of
severe heart failure in end-stage renal failure, as it has been
shown that endogenous cardioprotection is lost in severe heart
failure (22, 30, 34). In addition, renal failure seems to interact
with some protein kinases (33, 38) suggested to be involved in
the mechanism of ischemic preconditioning. Taken together,
the overall net changes in uremia seem to preserve the cardio-
protective effect of ischemic preconditioning; however, the
exact mechanisms remain to be elucidated in further studies.
In conclusion, our present study suggests that patients suf-
fering from long-term uremia may also benefit from cardio-
protection by ischemic preconditioning. This is particularly
important since acute myocardial infarction frequently occurs
in patients with late stages of renal failure. Because uremic
patients are regularly excluded from clinical trials, there is a
need for clinical studies to investigate the cardioprotective
effect of conditioning techniques in patients with chronic renal
failure suffering from acute myocardial infarction.
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